Raghu Kalluri, Professor and Chairman of Department of Cancer Biology at MD Anderson Cancer Center, shared a post on LinkedIn:
“It’s Official! Our Phase 1 clinical trial of iExosomes in metastatic pancreatic cancer is now published in Nature Communications.
Zero DLTs in this first – in – human trial of systemically administered engineered exosomes targeting KRAS G12D.
This was a truly heroic team effort by more than 90 colleagues across 17 departments, cores, and offices…start to finish….including non – human primate studies and manufacturing of clinical GMP – grade drug. Just 5 years from discovery in Kalluri Lab patients, and only possible at MD Anderson Cancer Center.
Special thanks to our clinical trial participants, their families, and to the authors: Valerie LeBleu Kalluri, Brandon Smaglo, MD, FACP, Krishnan Mahadevan, Michelle Kirtley, Kathleen McAndrews, Mayela Mendt, Sujuan Yang, Ana Maldonado, Hikaru Sugimoto, Maria Salvatierra, Luisa M. Solis Soto, Cara Haymaker, Rick Finch, Mihai Gagea-Iurascu, DVM, DVSc, DACVP, DABT, Adam C. Fluty, PhD, Steven Ludtke, J. Jack Lee, Abhinav Jain, Ph.D., Gauri Varadhachary, Rachna Shroff, MD, FASCO, Anirban Maitra, Elizabeth Shpall, Shubham Pant, and Raghu Kalluri.
Phase 2 is now underway.”
Title: Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates
Authors: Valerie Kalluri, Brandon Smaglo, Krishnan Mahadevan, Michelle Kirtley, Kathleen McAndrews, Mayela Mendt, Sujuan Yang, Ana Maldonado, Hikaru Sugimoto, Maria Salvatierra, Luisa Solis Soto, Cara Haymaker, Rick Finch, Mihai Gagea, Adam Fluty, Steven Ludtke, Jack Lee, Abhinav Jain, Gauri Varadhachary, Rachna Shroff, Anirban Maitra, Elizabeth Shpall, Shubham Pant, Raghu Kalluri
Read the full article on Nature Communications.
More posts featuring Raghu Kalluri.